Erigeron breviscapus injection combined with Qingkailing Injection was used in the treatment of 80 cases of cerebral infarction patients. Function test abnormalities were observed in 3 discussions after acute cerebral infarction. Following the infarction, intracellular calcium overload occurred, a large number of excitatory amino acids increased, free radical chain reactions were activated, and thromboxane A2 levels rose, leading to vascular spasm, intravascular coagulation, aggravation of penumbra ischemia, and expansion of the infarction area. At this time, protein kinase C (PKC) existing in the cytosol of brain cells could be induced and activated. PKC combines actively with the cell membrane and promotes intracellular calcium overload through multiple pathways, causing vascular spasm, degradation of cytoskeleton components, and playing an important role in damaging ischemic neurons. Traditional Chinese medicine has a long history and rich experience in treating stroke, identifying the basic pathogenesis as wind, phlegm, blood stasis, and evil heat blocking each other, resulting in blood disorder and chaos. This standard is often demonstrated in the virtual phase. In the acute stage, liver-wind, evil heat, phlegm, blood stasis, and internal organ closure are all standard symptoms. From the classification of 148 Down syndrome patients, phlegm, stasis, and heat were seen in 128 cases, accounting for 86.5% of the total. It is proposed that in the acute phase, it should mainly focus on clearing heat, resolving phlegm, promoting blood circulation to remove blood stasis, refreshing, and treating. Dengzhanhua Injection is composed of effective ingredients purified from Erigeron breviscapus flavonoids, with the function of promoting blood circulation and removing blood stasis. Qingkailing Injection evolved from Angong Niuhuang Wan, with the function of refreshing, clearing heat, and resolving phlegm. These two delivery platforms can correct the whole human blood disorders, promote the recovery of neurological functions, and rapidly improve the pathological condition of stroke. Modern experimental studies have confirmed that Erigeron breviscapus injection can block the translocation and activation of PKC, prevent cerebral ischemia-reperfusion-induced calcium influx and intracellular calcium overload, and has a protective effect on ischemic neuronal injury. It also significantly improves regional cerebral blood flow (rcBF) in patients with cerebral infarction. Qingkailing injection can reduce blood viscosity, improve blood rheological state, increase blood supply, enhance tissue tolerance to ischemia and hypoxia, and significantly reduce NMDA neurotoxicity induced by increased brain water and sodium content. It can also reduce the excitatory amino acids in injured brain tissue and reduce brain damage. The neurological symptoms of the treatment group improved significantly compared to the control group, especially the severe degree of neural function defect improved obviously. Confirming the use of Erigeron breviscapus injection and Qingkailing Injection in the treatment of cerebral infarction improves postischemic reperfusion cycle, reduces secondary oxygen free radicals, excitatory amino acids, and calcium overload damage, protects the ischemic penumbra of residual brain cells, lays a foundation for the recovery of neurological function, thereby reducing the disability rate and improving efficiency. Under the guidance of traditional Chinese medicine theory, combined with modern etiology and pharmacologic research foundations, this provides another alternative method for treating the acute phase of cerebral infarction.